Results 101 to 110 of about 33,292 (260)

Gut microbiota‐mediated immune and metabolic dysregulation in coronary artery disease progression and prognosis

iMeta, EarlyView.
The gut microbiota has emerged as a metabolically active endocrine‐like organ with a crucial role in coronary artery disease (CAD), yet its contribution to adverse clinical outcomes remains incompletely understood. In this prospective cohort of 319 participants, we integrated metagenomic and metabolomic profiling with longitudinal follow‐up over a ...
Honghong Liu, Siqin Feng, Lifeng Liang, Muyun Tang, Yifei Wang, Yiyang Wang, Zhiyu Zhang, Haiping Xing, Chenhong Zhang, Ran Tian, Shuyang Zhang   +10 more
wiley   +1 more source

Screening of AR Gene CAG Repeat Variations in Iranian Women with Endometriosis [PDF]

Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Arāk, 2016
Background: Endometriosis disease is considered as a common disease dependent on androgen hormones. Androgens have different effects on endometrial growth. Androgen receptor as a signal transduction pathway could have a key role in regulating the process.
Azam Fakhri, Soyar Sari, Ahmad Ebrahimi
doaj  

Intermediate CAG repeat expansion in the ATXN2 gene is a unique genetic risk factor for ALS--a systematic review and meta-analysis of observational studies.

PLoS ONE, 2014
Amyotrophic lateral sclerosis (ALS) is a rare degenerative condition of the motor neurons. Over 10% of ALS cases are linked to monogenic mutations, with the remainder thought to be due to other risk factors, including environmental factors, genetic ...
Ming-Dong Wang, James Gomes, Neil R Cashman, Julian Little, Daniel Krewski   +4 more
doaj   +1 more source

Technical Assessment of Preclinical Noninvasive Imaging Methods for Endometriosis Follow‐Up in Murine Models

iRADIOLOGY, EarlyView.
This schematic rapidly illustrates the diverse imaging modalities used in preclinical endometriosis research. It highlights optical techniques, such as bioluminescence, fluorescence, and nanoparticle‐assisted imaging, alongside non optical approaches like MRI, ultrasound, and PET, which are key tools in advancing diagnostic precision and understanding ...
Peyman Palay, Tayyebeh Zamani‐Badi, Zeinab Ghezelayagh, Kiandokht Kiani   +3 more
wiley   +1 more source

Method to Introduce Stable, Expanded, Polyglutamine-Encoding CAG/CAA Trinucleotide Repeats into CAG Repeat-Containing Genes [PDF]

BioTechniques, 2001
Michalik, Andrej, Kazantsev, Aleksey, Van Broeckhoven, Christine   +2 more
openaire   +4 more sources

Startups Driving Artificial Intelligence Into Clinical Dermatology

JEADV Clinical Practice, EarlyView.
ABSTRACT Artificial intelligence (AI) is rapidly transitioning from innovation to routine clinical application in dermatology. This review examines how AI‐enabled technologies are being developed and integrated across diverse clinical purposes and workflows.
Dominique Du Crest, Benjamin Miguel Monteagudo, Stanislas Vandier, Mullarkey Dan, Svedenhag Per, Jon Friis, Monisha Madhumita, Lilit Garibyan, Tu‐Anh Duong, Merete Haedersdal, Vinzent Kevin Ortner   +10 more
wiley   +1 more source

Hemodynamic Significance of APEXCT Coronary Angiography Combined With Dynamic CT Myocardial Perfusion Imaging in Assessing Restenosis After Coronary Stenting

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study aimed to evaluate the hemodynamic significance of in‐stent restenosis (ISR) by using a combined anatomical‐functional approach with photon‐counting CT coronary angiography (APEX‐CT CTA) and dynamic CT myocardial perfusion imaging (CT‐MPI). We prospectively enrolled 239 symptomatic patients at least 9 months after PCI.
Liang‐Shi Wang, Tian Bai, Ji‐Zhou Yan, Peng‐Yu Guan, Li‐Juan Wen, Hong Guo, Tian‐Yu Zhang   +6 more
wiley   +1 more source

Falls in Huntington's Disease: A Cross‐Sectional Analysis of Clinical Features and Potential Contributors

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Falls occur across all stages of Huntington's disease (HD) and are associated with poor quality of life and injury. However, there is limited information on falls in HD. Objective The aim was to investigate the clinical features potentially associated with falls in HD. Methods We conducted a cross‐sectional, analytical observational
Arthur Pena Ferreira, Sarah Edith Souza de Assis Leão, Ricardo Oliveira Horta Maciel, Débora Palma Maia, Aline Alvim Scianni, Francisco Eduardo Costa Cardoso   +5 more
wiley   +1 more source

A Severity‐Agnostic Atrophy Pattern in Spinocerebellar Ataxia Type 3: Volumetrics from ENIGMA‐Ataxia

Movement Disorders, EarlyView.
Background Spinocerebellar ataxia type 3 (SCA3) is a rare, inherited neurodegenerative disease characterized by progressive loss of motor coordination. Objectives We undertook a multisite magnetic resonance imaging study to profile the spatial spread of atrophy across the brain, determine whether atrophy preferentially maps onto specific functional ...
Jason W. Robertson, Isaac Adanyeguh, David J. Arpin, Tetsuo Ashizawa, Benjamin Bender, Fernando Cendes, Xi Chen, Giulia Coarelli, Léo Coutinho, Andreas Deistung, Imis Dogan, Alexandra Durr, Jennifer Faber, for the ESMI MR Study Group, Juan Fernandez‐Ruiz, Mónica Ferreira, Marcondes C. França, Sophia L. Göricke, Shuo Han, Thomas Klockgether, Chen Liu, Jun Luo, Alberto R.M. Martinez, Sergio E. Ono, Chiadi U. Onyike, Gülin Öz, for the EUROSCA MR Study Group, Henry Paulson, Jerry L. Prince, Kathrin Reetz, Thiago J.R. Rezende, Matthis Synofzik, Hélio A. Ghizoni Teive, Sophia I. Thomopoulos, Paul M. Thompson, Dagmar Timmann, David Vaillancourt, Bart van de Warrenburg, Judith van Gaalen, Xingang Wang, Philipp Wegner, Sarah H. Ying, Ian H. Harding, Carlos R. Hernandez‐Castillo   +43 more
wiley   +1 more source

Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025

Movement Disorders, EarlyView.
Abstract Background In the past decade, significant advances have improved our understanding of the mechanisms underlying HD pathobiology leading to several putative therapeutic targets for HD. Objective The aim was to describe the Huntington's disease (HD) drug development clinical pipeline.
Pavlina Konstantinova, Jenny Townhill, Juliana Bronzova, Viktoria Andreeva, Swati Sathe, Cristina Sampaio   +5 more
wiley   +1 more source